Zachary Roberts
Technik-/Wissenschafts-/F&E-Leiter bei ALLOGENE THERAPEUTICS, INC.
Vermögen: 95 718 $ am 31.05.2024
Profil
Zachary Roberts is currently the Chief Medical Officer & Executive Vice President at Allogene Therapeutics, Inc. He previously worked as the Director-Clinical Medical Research at Amgen, Inc. in 2015, the Vice President-Clinical Development at Kite Pharma, Inc. from 2018 to 2019, and the Chief Medical Officer at Instil Bio, Inc. from 2020 to 2022.
Dr. Roberts obtained his undergraduate degree from the University of Maryland and his doctorate from the University of Maryland School of Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.03.2024 | 38 287 ( 0,02% ) | 95 718 $ | 31.05.2024 |
Aktive Positionen von Zachary Roberts
| Unternehmen | Position | Beginn |
|---|---|---|
| ALLOGENE THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 03.01.2023 |
Ehemalige bekannte Positionen von Zachary Roberts
| Unternehmen | Position | Ende |
|---|---|---|
| INSTIL BIO, INC. | Technik-/Wissenschafts-/F&E-Leiter | 11.11.2022 |
| KITE PHARMA INC | Technik-/Wissenschafts-/F&E-Leiter | 01.05.2019 |
| AMGEN INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.07.2015 |
Ausbildung von Zachary Roberts
| University of Maryland | Undergraduate Degree |
| University of Maryland School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| INSTIL BIO, INC. | Health Technology |
| ALLOGENE THERAPEUTICS, INC. | Health Technology |
| AMGEN INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Kite Pharma, Inc.
 Kite Pharma, Inc. BiotechnologyHealth Technology Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam on 2009 and is headquartered in Santa Monica, CA. | Health Technology |